Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.60 |
| ▸ | MMP13 | P45452 | 2/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828863 | 0.84 | TNKS (0.57) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL1264068 | 0.80 | MAPT (0.58) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL11917092 | 0.79 | GUSB (0.66) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL11917093 | 0.78 | GUSB (0.72) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL4606203 | 0.77 | MMP13 (0.62) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL11917075 | 0.77 | GUSB (0.74) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL259489 | 0.77 | GUSB (0.74) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL873782 | 0.75 | GUSB (1.00) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL874285 | 0.74 | GUSB (0.62) | GUSBMMP13MMP2MMP9MMP8 | |
| SCHEMBL28761269 | 0.73 | RAB9A (0.80) | GUSBMMP13MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1768978-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006005914-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | GUSB 4804/4885MMP13 4482/4885MMP2 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.